Why and how to do Bayes for clinical trials: Our comments on the recent FDA draft guidance, and reactions to two comments by others

The Journal of the American Medical Association recently contacted me to ask for a comment on a recent Draft Guidance for Industry from the U.S. Food and Drug Administration on the use of Bayesian methodology in clinical trials of drug … Continue reading →